Login

Recent searches

No recent searches

Search options

Only available when logged in.
fosstodon.org is one of the many independent Mastodon servers you can use to participate in the fediverse.
Fosstodon is an invite only Mastodon instance that is open to those who are interested in technology; particularly free & open source software. If you wish to join, contact us for an invite.

Administered by:

Server stats:

9.8K
active users

fosstodon.org: AboutStatusProfiles directoryPrivacy policy

Mastodon: AboutGet the appKeyboard shortcutsView source codev4.3.7

#LongCovidKids

5 posts4 participants0 posts today
Public
Bass #AlleBurgers #EcoHumanist

#guustweet op X schreef:

Mark van 10 jaar heeft al 3 jaar #LongCovid. Naar schatting hebben 40.000 (!) kinderen de ziekte.

Podcast met #Zurhake (Sander Zurhake)
die duiding geeft over Long Covid, de expertisecentra, politiek, link met post acute infectieuze ziektes etc.

open.spotify.com/episode/19dGc

#LongCovidKids @LongcovidNieuws @whn

Spotify#1851 - Mark (10) heeft al drie jaar long covidDe Dag · Episode
Public
Bass #AlleBurgers #EcoHumanist

#SarsCoV2 Actueel risico volgens #LoCovid 12 april 2025

Het aantal virusdeeltjes in het riool is iets opgelopen, maar is nog steeds relatief laag vergeleken met de afgelopen drie jaar.

Recent verscheen onderzoek dat laat zien dat Covid de structuur en de werking van de hersenen van kinderen aantast. 1/2

locovid.nl/oversterfte-ziekte-

locovid.nlOversterfte, ziekte en verspreiding Covid19 2025-14 – Low Covid info & actie
#LongCovidKids
Public
Initiative #ProtectTheKids

"Der Junge, der keine Kraft zum Spielen hat" - berührende Spiegel-Reportage von Marlen Schubert über #LongCovidKids am Beispiel eines Achtjährigen aus Hamburg, der im Sommer 2022 nach einer Corona-Infektion schwer an ME/CFS erkrankt ist:
spiegel.de/gesundheit/me-cfs-b

Paywallfreie Archivansicht:
➡️ archive.ph/U8PnM

DER SPIEGEL · ME/CFS bei Kindern: Der Junge, der keine Kraft zum Spielen hatBy Marlen Schubert
Public
Tom Kindlon

Bateman Horne Center:

Part 2: Amy Mooney, MS, OTR/L, shares insights on managing Long COVID & ME/CFS in children.
⚡ Understanding symptoms & challenges
🛠️ Breaking the “Push-Crash” cycle
📚 Case examples & pacing tips

👉 Watch the full presentation: loom.ly/44buqr8
#lckids #longcovidkids #LongCOVID #MECFS @mecfs @longcovid

loom.ly- YouTubeEnjoy the videos and music you love, upload original content, and share it all with friends, family, and the world on YouTube.
Public
Bass #AlleBurgers #EcoHumanist

#globalhlthtwit on X wrote:

NOT peer reviewed yet. Children and adolescents face significantly higher risk of various post-Covid outcomes after REINFECTION with #SarsCoV2. Data supports prevention + vaccination policies for children.

medrxiv.org/content/10.1101/20

@whnnl @alleburgers
@ABScientist

medRxiv · Reinfection with SARS-CoV-2 in the Omicron Era is Associated with Increased Risk of Post-Acute Sequelae of SARS-CoV-2 Infection: A RECOVER-EHR Cohort StudyIMPORTANCE Post-acute sequelae of SARS-CoV-2 infection (PASC) remains a major public health challenge. While previous studies have focused on characterizing PASC and identifying its subphenotypes in children and adolescents following an initial SARS-CoV-2 infection, the risks of PASC with Omicron-variant reinfections remain unclear. Using a real-world data approach, this study investigates the risks of PASC following reinfections during the Omicron phase in the pediatric population. OBJECTIVE To investigate the risks of PASC diagnosis and 24 PASC symptoms and conditions after reinfection of SARS-CoV-2 during Omicron period in the pediatric population. DESIGN, SETTING, AND PARTICIPANTS This retrospective cohort study used data from the RECOVER consortium comprising 40 children’s hospitals and health institutions in U.S. between January 2022 and October 2023. EXPOSURES A second SARS-CoV-2 infection, confirmed by a positive polymerase-chain-reaction (PCR) or antigen tests, or a diagnose of COVID-19, occurring at least 60 days after the initial infection, compared to the initial infection. MAIN OUTCOMES AND MEASURES PASC was identified using two approaches: (1) the ICD-10- CM diagnosis code U09.9 and (2) a symptom-based definition including 24 physician-identified symptoms and conditions. Absolute risks of incident PASC were reported, and relative risks (RRs) were calculated by comparing the second infection episode with the first infection episode groups using a modified Poisson regression model, adjusting for demographic, clinical, and healthcare utilization factors through exact matching and propensity scoring matching. RESULTS A total of 465,717 individuals under 21 years old (mean [SD] age 8.17 [6.58] years; 52% male) were included. Compared to the first infection, a second infection was associated with significantly increased risk of an overall PASC diagnosis (RR, 2.08; 95% confidence interval [CI], 1.68-2.59), and with many specific conditions including: myocarditis (RR, 3.60; 95% CI, 1.46-8.86); changes in taste and smell (RR, 2.83; 95% CI, 1.41-5.67); thrombophlebitis and thromboembolism (RR, 2.28; 95% CI, 1.71-3.04); heart disease (RR, 1.96; 95% CI, 1.69 to 2.28); acute kidney injury (RR, 1.90; 95% CI, 1.38 to 2.61); fluid and electrolyte (RR, 1.89; 95% CI, 1.62 to 2.20); generalized pain (RR, 1.70; 95% CI, 1.48 to 1.95); arrhythmias (RR, 1.59; 95% CI, 1.45-1.74); abnormal liver enzyme (RR, 1.56; 95% CI, 1.24 to 1.96); fatigue and malaise (RR, 1.50; 95% CI, 1.38 to 1.64); musculoskeletal pain (RR, 1.45; 95% CI, 1.37 to 1.54); abdominal pain (RR, 1.42; 95% CI, 1.34 to 1.50); postural orthostatic tachycardia syndromes (POTS)/dysautonomia (RR, 1.35; 95% CI, 1.20 to 1.51); cognitive functions (RR, 1.32; 95% CI, 1.15 to 1.50); and respiratory signs and symptoms (RR, 1.29; 95% CI, 1.25 to 1.33). The risks were consistent across various organ systems, including cardiovascular, respiratory, gastrointestinal, neurological, and musculoskeletal systems. CONCLUSIONS AND RELEVANCE Children and adolescents face significantly higher risk of various PASC outcomes after reinfection with SARS-CoV-2. These findings suggest a cumulative risk of PASC and highlight the urgent need for targeted prevention strategies to reduce reinfections, which includes an increased emphasis on initial or re-vaccination of children. Question Do children and adolescents face an increased risk of post-acute sequelae of SARS-CoV-2 infection (PASC) following reinfection during the Omicron era? Findings During the post-acute phase, children and adolescents with reinfection are at statistically significant increased risk of incident PASC outcomes, including an overall PASC diagnosis and 24 most commonly complaints/symptoms/diagnoses associated with PASC. The risks remained consistent across different demographic and clinical subgroups. Meaning These findings underscore the significant long-term health risks associated with SARS-CoV-2 reinfection in children and adolescents. Public health strategies should prioritize reinfection prevention, including enhanced vaccination efforts, to mitigate the burden of PASC in the pediatric population. ### Competing Interest Statement Dr. Jhaveri is a consultant for AstraZeneca, Seqirus, Gilead, Sanofi; receives an editorial stipend from the Pediatric Infectious Diseases Society; research support from GSK; and royalties from Up To Date/Wolters Kluwer. All other co-authors have no conflicts of interest to report. ### Funding Statement This research was funded by the National Institutes of Health (NIH) Agreement OT2HL161847-01 as part of the Researching COVID to Enhance Recovery (RECOVER) program of research. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Ethnics committee/IRB of University of Pennsylvania waived ethical approval for this work. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes All data produced in the present study are available upon reasonable request. The results reported in this study are based on detailed individual-level patient data compiled as part of the RECOVER program. Due to the high risk of reidentification based on the number of unique patterns in the date, patient privacy regulations prohibit us from releasing the data publicly. The data are maintained in a secure enclave, with access managed by the program coordinating center to remain compliant with regulatory and program requirements. Please direct requests to access the data, either for reproduction of the work reported here or for other purposes, to the RECOVER EHR Pediatric Coordinating Center (recover{at}chop.edu).
#LongCovidKids
Public *
Bass #AlleBurgers #EcoHumanist

#ejustin46 on X wrote:

For CHILDREN, the risk of LONG COVID after a SECOND INFECTION is 2.08 TIMES GREATER compared to the FIRST INFECTION.
medrxiv.org/content/10.1101/20

🧵threadreaderapp.com/thread/190

#LongCovidKids #LongCovid @longcovid @alleburgers @whn @ABScientist

medRxiv · Reinfection with SARS-CoV-2 in the Omicron Era is Associated with Increased Risk of Post-Acute Sequelae of SARS-CoV-2 Infection: A RECOVER-EHR Cohort StudyIMPORTANCE Post-acute sequelae of SARS-CoV-2 infection (PASC) remains a major public health challenge. While previous studies have focused on characterizing PASC and identifying its subphenotypes in children and adolescents following an initial SARS-CoV-2 infection, the risks of PASC with Omicron-variant reinfections remain unclear. Using a real-world data approach, this study investigates the risks of PASC following reinfections during the Omicron phase in the pediatric population. OBJECTIVE To investigate the risks of PASC diagnosis and 24 PASC symptoms and conditions after reinfection of SARS-CoV-2 during Omicron period in the pediatric population. DESIGN, SETTING, AND PARTICIPANTS This retrospective cohort study used data from the RECOVER consortium comprising 40 children’s hospitals and health institutions in U.S. between January 2022 and October 2023. EXPOSURES A second SARS-CoV-2 infection, confirmed by a positive polymerase-chain-reaction (PCR) or antigen tests, or a diagnose of COVID-19, occurring at least 60 days after the initial infection, compared to the initial infection. MAIN OUTCOMES AND MEASURES PASC was identified using two approaches: (1) the ICD-10- CM diagnosis code U09.9 and (2) a symptom-based definition including 24 physician-identified symptoms and conditions. Absolute risks of incident PASC were reported, and relative risks (RRs) were calculated by comparing the second infection episode with the first infection episode groups using a modified Poisson regression model, adjusting for demographic, clinical, and healthcare utilization factors through exact matching and propensity scoring matching. RESULTS A total of 465,717 individuals under 21 years old (mean [SD] age 8.17 [6.58] years; 52% male) were included. Compared to the first infection, a second infection was associated with significantly increased risk of an overall PASC diagnosis (RR, 2.08; 95% confidence interval [CI], 1.68-2.59), and with many specific conditions including: myocarditis (RR, 3.60; 95% CI, 1.46-8.86); changes in taste and smell (RR, 2.83; 95% CI, 1.41-5.67); thrombophlebitis and thromboembolism (RR, 2.28; 95% CI, 1.71-3.04); heart disease (RR, 1.96; 95% CI, 1.69 to 2.28); acute kidney injury (RR, 1.90; 95% CI, 1.38 to 2.61); fluid and electrolyte (RR, 1.89; 95% CI, 1.62 to 2.20); generalized pain (RR, 1.70; 95% CI, 1.48 to 1.95); arrhythmias (RR, 1.59; 95% CI, 1.45-1.74); abnormal liver enzyme (RR, 1.56; 95% CI, 1.24 to 1.96); fatigue and malaise (RR, 1.50; 95% CI, 1.38 to 1.64); musculoskeletal pain (RR, 1.45; 95% CI, 1.37 to 1.54); abdominal pain (RR, 1.42; 95% CI, 1.34 to 1.50); postural orthostatic tachycardia syndromes (POTS)/dysautonomia (RR, 1.35; 95% CI, 1.20 to 1.51); cognitive functions (RR, 1.32; 95% CI, 1.15 to 1.50); and respiratory signs and symptoms (RR, 1.29; 95% CI, 1.25 to 1.33). The risks were consistent across various organ systems, including cardiovascular, respiratory, gastrointestinal, neurological, and musculoskeletal systems. CONCLUSIONS AND RELEVANCE Children and adolescents face significantly higher risk of various PASC outcomes after reinfection with SARS-CoV-2. These findings suggest a cumulative risk of PASC and highlight the urgent need for targeted prevention strategies to reduce reinfections, which includes an increased emphasis on initial or re-vaccination of children. Question Do children and adolescents face an increased risk of post-acute sequelae of SARS-CoV-2 infection (PASC) following reinfection during the Omicron era? Findings During the post-acute phase, children and adolescents with reinfection are at statistically significant increased risk of incident PASC outcomes, including an overall PASC diagnosis and 24 most commonly complaints/symptoms/diagnoses associated with PASC. The risks remained consistent across different demographic and clinical subgroups. Meaning These findings underscore the significant long-term health risks associated with SARS-CoV-2 reinfection in children and adolescents. Public health strategies should prioritize reinfection prevention, including enhanced vaccination efforts, to mitigate the burden of PASC in the pediatric population. ### Competing Interest Statement Dr. Jhaveri is a consultant for AstraZeneca, Seqirus, Gilead, Sanofi; receives an editorial stipend from the Pediatric Infectious Diseases Society; research support from GSK; and royalties from Up To Date/Wolters Kluwer. All other co-authors have no conflicts of interest to report. ### Funding Statement This research was funded by the National Institutes of Health (NIH) Agreement OT2HL161847-01 as part of the Researching COVID to Enhance Recovery (RECOVER) program of research. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Ethnics committee/IRB of University of Pennsylvania waived ethical approval for this work. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes All data produced in the present study are available upon reasonable request. The results reported in this study are based on detailed individual-level patient data compiled as part of the RECOVER program. Due to the high risk of reidentification based on the number of unique patterns in the date, patient privacy regulations prohibit us from releasing the data publicly. The data are maintained in a secure enclave, with access managed by the program coordinating center to remain compliant with regulatory and program requirements. Please direct requests to access the data, either for reproduction of the work reported here or for other purposes, to the RECOVER EHR Pediatric Coordinating Center (recover{at}chop.edu).
Public *
Denis - The COVID info guy -

Tests show emotional, behavioral problems in adolescents with long COVID.

"A clinical survey of 85 pediatric long-COVID patients in Bavaria, Germany, reveals high levels of fatigue, loss of motivation, difficulty concentrating and maintaining attention, worsened mood, and greater anxiety"

Source: cidrap.umn.edu/covid-19/tests-

Study: bmcinfectdis.biomedcentral.com

#LongCOVIDKids @auscovid19

CIDRAPTests show emotional, behavioral problems in adolescents with long COVID
Public
MEActNOW

💔
Just had another talk with a mom who’s kid is treated for depression with antidepressants that aren’t helping. Turns out she always crashes after she does something, has POTS symptoms and cold hand and feet and most #mecfs symptoms. 3 weeks had the same talk with another mom.

#LongCovidKids
Public
Jeweljam

👀 If you can’t make it it will be on their YouTube afterwards. #CovidIsNotOver #COVIDisAirborne #N95sSaveLives #CleanAirNow #LongCovid #LongCovidKids #TogetherWeCan #ShareTheCare us06web.zoom.us/webinar/regist

ZoomWelcome! You are invited to join a webinar: Exploring Long COVID Treatments: First-line, Promising, and Experimental. After registering, you will receive a confirmation email about joining the webinar.Panelists: David Putrino, PhD - Professor in the Department of Rehabilitation and Human Performance at the Icahn School of Medicine at Mount Sinai in New York City and is the Nash Family Director of the Cohen Center for Recovery from Complex Chronic Illness. David trained as a physiotherapist in Australia before completing a PhD in Neuroscience. Since the beginning of the COVID-19 pandemic in 2020, David has been recognized globally as a leading expert in the assessment, treatment and underlying pathophysiology of Long COVID. His team has managed the care of over 3000 people with Long COVID and published multiple peer-reviewed scientific papers on the topic. In 2019, he was named "Global Australian of the Year" for his contributions to healthcare. Leo Galland, MD - Physician at Leo Galland MD in New York City, international bestselling author, and recipient of the Linus Pauling Award from the Institute of Functional Medicine. Leo has been diagnosing and treating Long COVID patients since 2021 and brings a functional medicine approach to Long COVID management, with areas of focus on the gut microbiome, mitochondrial health, and tickborne diseases. Stuart Malcolm, MD - Physician and Medical Director at RTHM. Clinic Stuart has treated hundreds of Long COVID patients since March of 2020 and brings a wealth of experience, knowledge and a true passion for care to the table. He has a particular interest in endothelial and mitochondrial dysfunction, iron dysregulation, EBV reactivation and SARS-CoV2 viral antigen persistence in this patient group. Jennifer Curtin, MD - RTHM Chief Medical Officer and Cofounder. Jennifer’s area of clinical focus has been ME/CFS, Long COVID, and frequently co-morbid conditions like POTS. She’s a member of the ME/CFS Clinician Coalition and on the Scientific Advisory Board of MEAction. Her patient-centered approach integrates the latest research findings into clinical practice for IACCs.
ExploreLive feeds
About